Asked by: Lord Weir of Ballyholme (Democratic Unionist Party - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what estimate they have made of the number of excess deaths that have arisen as a consequence of restrictions and lockdowns arising from the COVID-19 pandemic.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Excess deaths are the difference between the number of registered deaths and the number expected based on previous trends. Weekly estimates of excess deaths are published by the Office for National Statistics (ONS). Its latest data shows that for the years 2020 to 2022, there were an estimated 151,506 estimated excess deaths in England.
It is likely that deaths from COVID-19 were a large driver of excess deaths in the peak pandemic periods. Deaths were above the expected level for most of the second half of 2021, and from March 2022 until the summer of 2023; however, deaths have been below the expected level for most weeks since then.
The drivers of excess deaths are not fully understood, and the excess is likely to be the net effect of many complex and potentially related factors. The attribution of excess deaths to these factors is complex and beyond the scope of the ONS methodology. The UK Health Security Agency has estimated the excess deaths due to acute factors, such as heatwaves, cold snaps, COVID-19 and influenza.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Ministry of Justice:
To ask the Secretary of State for Justice, how many people have been convicted for breaching covid-19 restrictions since January 2022.
Answered by Gareth Bacon - Parliamentary Under-Secretary (Ministry of Justice)
It has not proved possible to respond to the hon. Member in the time available before Prorogation.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, on what date NHS England informed patients receiving the Oxford-AstraZeneca Covid-19 vaccine that there were safety risks of vaccine-induced thrombosis with thrombocytopenia associated with the vaccine.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
To ensure informed consent was given by patients who received the AstraZeneca COVID-19 vaccine, all vaccination sites were instructed to follow consent guidance in line with the recommendations set out in chapter two of the UK Health Security Agency Green Book on vaccinations and immunisations.
Healthcare organisations administering any COVID-19 vaccinations are responsible for drawing up their own policies for obtaining informed consent, and health professionals overseeing or administering COVID-19 vaccines are responsible for ensuring that valid consent has been obtained. This would normally involve a discussion with the clinician prior to the administration of the vaccine, and individuals will also have had access to guides and patient information leaflets which provided details about the vaccine, how it is administered, possible side effects, and other warnings and precautions to take.
Regarding the very rare adverse events of concurrent thrombosis and thrombocytopenia associated with the AstraZeneca COVID-19 vaccine, NHS England notified healthcare organisations administering the COVID-19 vaccinations immediately following the updated advice from the independent Joint Committee on Vaccination and Immunisation published on 7 April 2021, and then again following updated advice on 7 May 2021. In these updates, sent via system letters, NHS England set out the next steps for healthcare organisations and clinicians, including on the consent process.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps NHS England took to ensure that informed consent was given by recipients of the Oxford-AstraZeneca covid-19 vaccine.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
To ensure informed consent was given by patients who received the AstraZeneca COVID-19 vaccine, all vaccination sites were instructed to follow consent guidance in line with the recommendations set out in chapter two of the UK Health Security Agency Green Book on vaccinations and immunisations.
Healthcare organisations administering any COVID-19 vaccinations are responsible for drawing up their own policies for obtaining informed consent, and health professionals overseeing or administering COVID-19 vaccines are responsible for ensuring that valid consent has been obtained. This would normally involve a discussion with the clinician prior to the administration of the vaccine, and individuals will also have had access to guides and patient information leaflets which provided details about the vaccine, how it is administered, possible side effects, and other warnings and precautions to take.
Regarding the very rare adverse events of concurrent thrombosis and thrombocytopenia associated with the AstraZeneca COVID-19 vaccine, NHS England notified healthcare organisations administering the COVID-19 vaccinations immediately following the updated advice from the independent Joint Committee on Vaccination and Immunisation published on 7 April 2021, and then again following updated advice on 7 May 2021. In these updates, sent via system letters, NHS England set out the next steps for healthcare organisations and clinicians, including on the consent process.
Asked by: Lord Birt (Crossbench - Life peer)
Question to the Cabinet Office:
To ask His Majesty's Government what percentage of annual vehicle theft in the UK is accomplished by offenders cloning the signal from the vehicle owner’s remote locking device.
Answered by Baroness Neville-Rolfe - Minister of State (Cabinet Office)
The information requested falls under the remit of the UK Statistics Authority.
Please see the letter attached from the National Statistician and Chief Executive of the UK Statistics Authority.
The Lord Birt
House of Lords
London
SW1A 0PW
9 May 2024
Dear Lord Birt,
As National Statistician and Chief Executive of the UK Statistics Authority, I am responding to your Parliamentary Question asking what percentage of annual vehicle theft in the UK is accomplished by offenders cloning the signal from the vehicle owner’s remote locking device (HL4379).
The Office for National Statistics (ONS) publish figures on the levels and trends of crime in England and Wales primarily based on two sets of crime statistics: the Crime Survey for England and Wales (CSEW) and police recorded crime data. The CSEW provides estimates of the prevalence of crime and different crime types as experienced by victims, which may not always be reported to the police.
Table 1 shows an estimate of the percentage of households who have experienced theft of a vehicle, where the method of entry into the vehicle was through manipulation of the signal from the remote locking device. This is taken from our Nature of crime: vehicle-related theft tables for the year ending March 2023 published on 3 April 2024. Due to the suspension of the CSEW during the coronavirus (COVID-19) pandemic, data are not available for the year ending March 2021 and the year ending March 2022.
Unfortunately, we do not hold any information from police-recorded crime which shows what percentage of annual vehicle theft in England and Wales is accomplished by offenders cloning the signal from the vehicle owner’s remote locking device.
Crime and justice statistics for Scotland can be found on the Scottish Government website and for more information please contact Justice_Analysts@gov.scot. The Northern Ireland Statistics and Research Agency (NISRA) are responsible for producing crime and justice statistics for Northern Ireland and can be contacted at statistics.research@justice-ni.x.gsi.gov.uk.
Yours sincerely,
Professor Sir Ian Diamond
Table 1: Estimated percentage of theft of vehicles where method of entry was through manipulation of the signal from remote locking device, year ending March 2019 to year ending March 2023 CSEW
England and Wales - household incidents, percentages | |||
| Apr’18 to Mar’19 | Apr’19 to Mar’20 | Apr’22 to Mar’23 [1] |
Entry to vehicle through manipulation of signal from remote locking device[2] | 13 | 36 | 40 |
Unweighted base – number of incidents[3] | 46 | 50 | 51 |
Source: Office for National Statistics – Crime Survey for England and Wales
[1]CSEW estimates for the year ending March 2023 have been temporarily suspended of their National Statistics status. Caution should be taken when interpreting these estimates because of the impact of lower response rates, and reduced interviewer numbers on the quality of the estimates.
[2]This category was added into the survey from the year ending March 2019.
[3]Estimates that are based on fewer than 50 respondents should be interpreted with caution.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department has not directly received data from AstraZeneca regarding potential adverse effects of their COVID-19 vaccine Vaxzevria, as it is not the appropriate body to receive this information. It instead relies on the expert advice of the Medicines and Healthcare products Regulatory Agency (MHRA).
All vaccine manufacturers have a legal responsibility to mitigate risk and monitor the safety and performance of vaccines throughout the product lifecycle. This includes a legal responsibility to transmit reports of suspected adverse reactions received directly to the MHRA. Following the MHRA’s receipt of the first Yellow Card reports of suspected thrombosis and associated thrombocytopaenia associated with the Vaxzevria vaccine in February 2021, AstraZeneca provided the Commission on Human Medicines’ Vaccine Benefit Risk Expert Working Group an analysis of the age stratified risk of thrombosis with thrombocytopenia associated with the AstraZeneca vaccine. This was assessed by the Commission on Human Medicines, with the Patient Information updated to state the risks of these events.
Asked by: Fabian Hamilton (Labour - Leeds North East)
Question to the Foreign, Commonwealth & Development Office:
To ask the Deputy Foreign Secretary, if he will make an assessment of the (a) adequacy of the transparency of the Chinese government on their handling of the covid-19 outbreak and (b) implications for his policies of the protest by Zhang Yongzhen.
Answered by Anne-Marie Trevelyan - Minister of State (Foreign, Commonwealth and Development Office)
We are aware of the protest made by Zhang Yongzhen. Clearly there are questions that still need to be answered about the origin and spread of COVID-19, not least so we can ensure we are better prepared for future pandemics. We are not going to rule anything out until a robust, transparent and science-led review has taken place. The UK continues to support the World Health Organisation (WHO) in its expert study of the origins of Covid-19. It is important that China and other countries cooperate fully with the researchers.
Asked by: Andrew Bridgen (Independent - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will publish a list of medical professionals (a) warned, (b) suspended and (c) with attempted suspensions for raising concerns over (i) covid-19 treatments and (ii) the pandemic response.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The General Medical Council (GMC) is the independent regulator of all medical doctors practising in the United Kingdom. It sets and enforces the standards all doctors must adhere to. The GMC is independent of Government, and directly accountable to Parliament. The Medical Practitioners Tribunal Service (MPTS) operates separately from the investigatory role of the GMC, and makes independent decisions about whether doctors are fit to practise medicine. The hearings and decisions of the MPTS are published and available to access online.
Asked by: Gavin Williamson (Conservative - South Staffordshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help increase the provision of covid-19 booster vaccinations to community pharmacies.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Community pharmacies have been taking part in the COVID-19 vaccination programme since January 2021. NHS England has recently changed the model for procuring COVID-19 vaccination services to an opt-in model. All community pharmacies who applied, and met the minimum requirements, received a contract to deliver COVID-19 vaccinations. This enabled more pharmacies to support the autumn 2023/24 booster campaign, administering COVID-19 vaccinations alongside flu vaccinations, which are also increasingly being administered in these settings.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of including carers in the eligibility criteria for the Spring 2024 Covid Vaccination Programme.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Government remains committed to protecting those most vulnerable to COVID-19 through vaccination, as guided by the independent Joint Committee on Vaccination and Immunisation (JCVI). On 7 February 2024, the JCVI published further advice on the United Kingdom’s COVID-19 vaccination programme. The JCVI advice is that a COVID-19 vaccine should be offered in spring 2024 to those at greatest risk of serious disease, and who are therefore most likely to benefit from vaccination. Those eligible are: adults aged 75 years old and over; residents in a care home for older adults; and individuals aged six months old and over who are immunosuppressed, as defined in chapter 14a of the UK Health Security Agency Green Book. The JCVI’s advice for spring 2024, including the approach to eligibility, is available via the following link:
The Government has accepted this advice, and the spring 2024 COVID-19 vaccination programme is now in progress. The spring programme is targeted to those at highest risk of serious outcomes from COVID-19. Whilst carers as a group are therefore not recommended for vaccination in this programme, any carer who falls within one of the above cohorts will be eligible. Everyone who is eligible is encouraged to take up the offer of spring COVID-19 vaccination.